Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.

The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Shares of Merck slid Tuesday in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling ...

Analysts have had mixed feelings about Merck in recent years, with concerns the company, like other big pharmaceuticals, isn't doing enough to ensure that its pipeline of products remains robust in ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...